NMTC NeuroOne Medical Technologies Corp

$NMTC StereoCED™ has reached another important development milestone. We successfully completed three separate large-animal procedures in our ongoing preclinical epilepsy research program evaluating StereoCED™ for targeted drug delivery and electrophysiological monitoring in the brain. Using a robotic workflow, researchers established the planned trajectory, placed our anchor bolt and advanced the StereoCED™ drug delivery electrode and catheter to the targeted region. In two of the three procedures, our drug delivery electrodes both delivered a study agent directly into targeted brain tissue and recorded intracranial electrophysiological activity from those same targeted regions. The successful repeatability demonstrated across these procedures provides additional confidence as we continue progressing toward the planned launch of StereoCED™ for human investigational clinical studies later this quarter.

$NMTC We continue to see progress across our commercial business. In our latest quarter, NeuroOne reported $2.0M in product revenue, up 16% year over year, with product gross margin reaching 59.9%. We remain focused on continued execution as we support our existing portfolio and advance the broader opportunities ahead.

$NMTC We are expanding the U.S. commercialization of our FDA-cleared OneRF® Trigeminal Nerve Ablation System through a new distribution agreement covering key Southern California counties, including the Los Angeles metropolitan area. This agreement marks another step in broadening commercial access to OneRF® and expanding our presence across important U.S. markets. As we continue our commercialization efforts, we remain focused on bringing our technology to more physicians and expanding access for patients suffering from trigeminal neuralgia. $GMED $BSX

$NMTC what are you doing NueroOne?! Burned up 95% of shareholder value while your ceo continues to say we’re almost to commercialization. Get creative. Work harder and maybe give up your salary until you stop burning so much cash you have to dilute continuously. Even your new biz dev guy is dumping shares. Shows a lot of optimism. End rant. Wish I never came across this turd

$NMTC headlines here earlier. "today reported the successful completion of three separate large-animal procedures using its next-generation StereoCED™ platform. In two of the three procedures, NeuroOne’s drug delivery electrodes both delivered a study agent directly into targeted brain tissue and recorded intracranial electrophysiological activity from the same targeted regions. This is a combination the Company believes has not been previously demonstrated and represents a first in the field of convection-enhanced delivery."

$NMTC The second production facilities can’t come fast enough. Revenue can be recognized, but also I’m sure there are patients out there eager to get treated.

$NMTC $GMED $BSX it's called an Easter Egg....hints....tagged Boston Scientific and Globus Medical....who are we in talks with? Top tier

$nmtc advanced discussions for over a year now??? How long has it been this was in a March letter

$NMTC Wambeke added 33,333 shares on 8.27.26 at an avg price of $2.01. Split adjusted: 1M to 166,666 + 33,333 = 199,999 shares now.

$NMTC wow the new biz dev guy Wambecke had 1m shares now down to 199k that’s not looking good for this

$NMTC if they knew the pump would fail, would they still have tortured those poor cats with their useless contraption?

$NMTC haha comical. Should have unloaded years worth of holdings at the halt and never looked back